How Orphan Therapeutics Accelerator uses Vibe Bio for rare disease due diligence, pipeline & competitive analysis, & in-licensing strategy.

Learn how Vibe Bio helped Incite accelerate sarcoma drug discovery with unbiased ranking and AI-powered compound analysis.

Even with databases, access to prior knowledge in biotech BD teams often breaks down. The antidote is simple : build durable organizational memory. AI can help.

MHC-E is a highly conserved, non-polymorphic MHC protein that engages inhibitory and activating receptors on natural killer (NK) cells and T cells and can also present antigens to T cell receptors. NK cell responses driven by activating receptor interactions with MHC-E are implicated in controlling chronic viral infections and cancer. Immunotherapeutic targeting of interactions between MHC-E and inhibitory receptors to increase the activation of NK cells and T cells shows promise in improving antitumour immune responses. Furthermore, MHC-E-restricted CD8+ T cells elicited by cytomegalovirus-based vaccines might, for certain infections and cancers, be more effective than CD8+ T cells restricted by classical MHC class I or class II molecules. The ability of MHC-E to regulate or mediate both innate and adaptive immune responses independently of the MHC haplotype of an individual raises the possibility of new, universally effective vaccines and immunotherapies for infectious disease and ca

Welcome to the Vibe Bio newsletter — your monthly window into the breakthroughs, bold ideas, and collective progress driving our mission: every cure for every community.

Adenosine receptors (ARs: A1AR, A2AAR, A2BAR, and A3AR) are crucial therapeutic targets; however, developing selective, efficacious drugs for them remains a significant challenge. Here, we present high-resolution cryo-electron microscopy (cryo-EM) structures of the human A3AR in three distinct functional states: bound to the endogenous agonist adenosine, the clinically relevant agonist Piclidenoson, and the covalent antagonist LUF7602. These structures, complemented by mutagenesis and pharmacological studies, reveal an A3AR activation mechanism that involves an extensive hydrogen bond network from the extracellular surface down to the orthosteric binding site. In addition, we identify a cryptic pocket that accommodates the N6-iodobenzyl group of Piclidenoson through a ligand-dependent conformational change of M1745.35. Our comprehensive structural and functional characterisation of A3AR advances our understanding of adenosine receptor pharmacology and establishes a foundation for devel

This webinar offers an AI buying guide for BD&L executives, including a framework for evaluating and choosing the right AI solutions to achieve results.

Facing a flood of biopharma assets? Learn how AI can help your BD team cut through the noise, gain confidence, and act with purpose.

Discover how top biopharma BD teams find diamonds in the rough by prioritizing strategic clarity, disciplined pipeline triage, and asset tracking.

An AI software company with a venture capital arm, our mission at Vibe Bio is to find every cure for every community. We help biopharmas make strategic drug pipeline decisions with greater speed and a...

The ability to make disciplined, well-informed decisions around portfolio strategy and asset prioritization in biopharma is more important than ever

An AI software company with a venture capital arm, our mission at Vibe Bio is to find every cure for every community. We help biopharmas make strategic drug pipeline decisions with greater speed and a...

Surrogate outcomes play an important role in modern healthcare research. Join us for this webinar where our experts will focus on methods and guidelines for establishing surrogate outcomes and how the...

SARS-CoV-2 entry into host cells is mediated by the spike protein, which drives membrane fusion. While cryo-EM reveals stable prefusion and postfusion conformations of the spike, the transient fusion intermediate states during the fusion process remain poorly understood. Here, we design a near-native viral fusion system that recapitulates SARS-CoV-2 entry and use cryo-electron tomography (cryo-ET) to capture fusion intermediates leading to complete fusion. The spike protein undergoes extensive structural rearrangements, progressing through extended, partially folded, and fully folded intermediates prior to fusion-pore formation, a process that depends on protease cleavage and is inhibited by the WS6 S2 antibody. Upon interaction with ACE2 receptor dimer, spikes cluster at membrane interfaces and following S2’ cleavage concurrently transition to postfusion conformations encircling the hemifusion and initial fusion pores in a distinct conical arrangement. S2’ cleavage is indispensable fo

Beneficiaries with 4 or more COVID-19 vaccine doses had a 39% lower rate of long COVID.

A map of microbiome–metabolome dynamics in people with type 2 diabetes identifies over 500 blood metabolites associated with impaired glucose control, with approximately one-third linked to an altered...

Many medical conditions affect only women, or affect them disproportionately, but women's health has historically been neglected in medical research. In this collection, we look at the gender gap in h...

Compass awaits Phase 3 COMP360 trial results for treatment-resistant depression amid renewed optimism for psychedelics.

With its AI foundation model and platform, Somite AI aims to overcome the key challenges of current lab-based stem cell development.

Initial clinical data from Genocury and EsoBiotec shows promise for in vivo CAR-T therapy, with complete remission in lymphoma and myeloma patients without lymphodepletion.

Jay Andersen, a pioneer in pharmaceutical decision-making, shared lessons developing portfolio management & probability assessment methods.

The Orphan Therapeutics Accelerator (OTXL), a non-profit biotech organization focused on completing development and commercializing therapies for ultra-rare ...

Pharma’s business development and licensing (BD&L) teams are navigating a complex marketplace and traditional approaches aren't working.

Biopharma business development and scientific teams are under a lot of pressure to identify the next big program for their indication and strategy.

The FDA approved a new antibiotic for UTIs from drugmaker GSK. The drug, Blujepa, is for women and girls ages 12 and up.

I recently sat down with a Top 20 pharmaceutical company to discuss their goals and struggles for the year ahead and how pharma portfolio analytics fits in.

Recently, I had a conversation with Dr. Kanya Rajangam, to discuss current perceptions about Chinese biotech, opportunities, language challenges, and risks.

Let’s explore the four most common use cases for an AI-powered drug pipeline analysis platform and how they support strategic decision-making in biopharma.

Eigen is a biotechnology company developing therapies that make cancer easier to find and eliminate. Eigen is focused on the development of “priming” therapies, therapies that help targeted therapies ...

Vibe Bio is uniquely positioned as both a cutting-edge artificial intelligence (AI) software company and a venture fund dedicated to supporting and advancing biotech research and development.